Wasatch Clinical Research, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$750	1
2022	Research	$12,392	2
2021	Research	$53,088	8
2020	Research	$115,396	10
2019	Research	$186,329	76

Breakdown

Who paid Research payments · program years 2019–2023

Mitsubishi Tanabe Pharma Development America, Inc. $166,737 5 payments
Eisai Inc. $134,759 72 payments
Teva Pharmaceuticals USA, Inc. $52,284 15 payments
AxoGen $13,425 4 payments
Amgen Inc. $750 1 payment

Studies the money was for Research payments · program years 2019–2023

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women with Endometriosis Experiencing Endometrial Related Pain $166,737 5 payments
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $134,759 72 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $52,284 15 payments
Study of Axoguard Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE) $13,425 4 payments
Medication Overuse Headache Study (MOH)_ $750 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.